hydrazine has been researched along with Myelodysplastic Syndromes in 47 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (12.77) | 29.6817 |
| 2010's | 27 (57.45) | 24.3611 |
| 2020's | 14 (29.79) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, R; Huang, L; Liu, C; Liu, Z; Tian, M | 1 |
| Ding, K; Duan, L; Fu, R; Guo, Y; Liu, Z; Shen, H | 1 |
| Biemond, BJ; Boersma, RS; Chalandon, Y; de Weerdt, O; Deeren, D; Efthymiou, A; Fehr, M; Graux, C; Gregor, M; Heim, D; Janssen, JJWM; Jongen-Lavrencic, M; Klein, SK; Legdeur, MCJC; Löwenberg, B; Manz, M; Ossenkoppele, GJ; Pabst, T; Sinnige, HAM; Spertini, O; Stüssi, G; Tick, LW; van der Poel, MWM; van Norden, Y; van Obbergh, F; van Sluis, G; Westerweel, PE | 1 |
| Boucher, R; Bowen, D; Cargo, C; Coulthard, HC; Culligan, D; Dennis, M; Jackson, A; Metzner, M; Moore, R; O'Sullivan, J; Raghavan, M; Sternberg, A; Vyas, P | 1 |
| Grosicki, S; Lawniczek, T; Mittelman, M; Platzbecker, U; Selleslag, D; Zhu, Z | 1 |
| Kulasekararaj, AG; Trikha, R | 1 |
| Patel, BJ; Sekeres, MA | 1 |
| Criscuolo, M; Cupelli, E; D'Alò, F; De Stefano, V; Fabiani, E; Falconi, G; Fianchi, L; Hohaus, S; Pagano, L; Zangrilli, I | 1 |
| Al Ali, N; Duong, VH; Komrokji, RS; Lancet, JE; List, AF; Padron, E; Sallman, D; Zhang, L | 1 |
| Artz, AS; Bishop, M; Cooperrider, JH; Fulton, N; Kosuri, S; Larson, RA; Liu, H; Stock, W | 1 |
| Babushok, DV; Sun, L | 1 |
| Abdel-Wahab, O; Alvarez, K; Chung, SS; Gönen, M; Klimek, VM; Mi, X; Paffenholz, SV; Park, JH; Penson, AV; Rampal, RK; Sen, F; Sigler, A; Stein, EM; Tallman, MS; Taylor, J | 1 |
| Albitar, M; Barranta, E; Calvo, KR; Dunbar, CE; Feng, X; Giudice, V; Groarke, E; Gutierrez-Rodrigues, F; Kajigaya, S; Lotter, J; Olnes, MJ; Parikh, AR; Patel, BA; Scheinberg, P; Shalhoub, R; Townsley, DM; Vicente, A; Weinstein, B; Winkler, T; Wu, CO; Young, NS | 1 |
| Ades, PL; Al Jijakli, A; Azerad, MA; Berceanu, A; Beyne-Rauzy, O; Broner, J; Cherait, A; Cluzeau, T; Comont, T; Cony-Makhoul, P; Dimicoli, S; Fenaux, P; Gaudin, C; Giraud, JT; Gruson, B; Guerveno, C; Guillaume, T; Gyan, E; Jachiet, V; Laribi, K; Le Clech, L; Meunier, M; Sanhes, L; Santana, C; Slama, B; Torregrosa, J | 1 |
| Altrock, E; Boch, T; Danner, J; Darwich, A; Flach, J; Haselmann, V; Hofmann, WK; Jann, JC; Jawhar, A; Jawhar, M; Knaflic, A; Marx, A; Mehralivand, A; Metzgeroth, G; Nolte, F; Nowak, D; Nowak, V; Obländer, J; Palme, I; Riabov, V; Schmitt, N; Steiner, L; Streuer, A; Uhlig, S; Weimer, N; Weis, CA; Xu, Q | 1 |
| Dodillet, H; Kreuzer, KA; Monsef, I; Skoetz, N | 1 |
| Afanasyev, B; Anagnostopoulos, A; Brenner, B; Denzlinger, C; Garcia-Delgado, R; Grosicki, S; Mittelman, M; Nagler, A; Platzbecker, U; Portella, MSO; Rossi, G; Selleslag, D; Wong, RSM; Zhu, Z | 1 |
| Shastri, A; Verma, AK | 1 |
| Buckstein, R | 1 |
| Alvarado, Y; Bodden, K; Borthakur, G; Bueso-Ramos, C; DiNardo, CD; Ferrajoli, A; Garcia-Manero, G; Kadia, TM; Khoury, J; Konopleva, M; Pemmaraju, N; Swaminathan, M; Yearby, B | 1 |
| Caillon, H; Chevallier, P; Dejoie, T; Garnier, A; Guillaume, T; Lebourgeois, A; Peterlin, P; Ropert-Bouchet, M | 1 |
| Afanasyev, B; Bonifazi, F; Bosman, P; Bruno, B; Cortelezzi, A; de Latour, RP; Dreger, P; Drénou, B; Drexler, B; Dufour, C; Ecsedi, M; Eikema, DJ; Garnier, A; Giammarco, S; Halkes, CJM; Knol-Bout, C; Lanino, E; Lengline, É; Ljungman, P; Maschan, A; Onofrillo, D; Passweg, J; Patriarca, A; Pioltelli, P; Pulanic, D; Risitano, AM; Rovó, A; Serventi-Seiwerth, R; Tournilhac, O | 1 |
| Barcellini, W; Cassin, R; Fattizzo, B; Levati, G | 1 |
| Pathak, S; Roth, M; Steidl, U; Verma, A | 1 |
| Gauchan, D; Gedeon, D; Maroules, M; Shaaban, H | 1 |
| Álvarez Román, MT; Arias-Salgado, EG; Butta, NV; de Paz, R; Fernández Bello, I; Jiménez Yuste, V; Martín Salces, M | 1 |
| Bhagat, T; Braunschweig, I; Roth, M; Schinke, C; Steidl, U; Tamari, R; Verma, A; Will, B | 1 |
| Cherif, H; Chowdhury, O; Garelius, H; Hellström-Lindberg, E; Jacobsen, SE; Lorenz, F; Saft, L; Svensson, T | 1 |
| Höchsmann, B; Körper, S; Schrezenmeier, H | 1 |
| Locatelli, F; Merli, P; Palumbo, G; Strocchio, L; Vinti, L | 1 |
| Kambhampati, S; Li, W; Morrone, K; Steidl, U; Verma, A; Will, B | 1 |
| Abboud, C; Araujo, S; Bennett, J; Chan, G; Chen, CY; Cheng, G; Chiou, TJ; Dougherty, S; Feigert, J; Giagounidis, A; Gorin, NC; Götze, K; Greenberg, P; Jang, JH; Johnson, B; Kambhampati, S; Kamel, YM; Kim, YJ; Lee, JH; Lyons, R; Mannino, F; Platzbecker, U; Ruggeri, M; Santini, V; Stone, N; Verma, A; Wong, RS; Yeh, SP | 1 |
| Al Ali, N; Duong, VH; Komrokji, RS; Lancet, JE; List, AF; Padron, E; Ramadan, H; Zhang, L | 1 |
| Altman, J; Dinner, S; Frankfurt, O; Gao, J; Helenowski, I; McMahon, BJ; Stein, BL; Waisbren, J | 1 |
| Choy, KW; Doery, JC; Wijeratne, N | 1 |
| Alati, C; Avanzini, P; Balleari, E; Bocchia, M; Bova, I; Buccisano, F; Carluccio, P; Cortelezzi, A; Cufari, P; D'Errigo, MG; Fenaux, P; Germing, U; Impera, S; Kulasekararaj, A; Latagliata, R; Liberati, AM; Mancini, S; Molteni, A; Morabito, F; Niscola, P; Oliva, EN; Palumbo, GA; Poloni, A; Salutari, P; Salvi, F; Sanpaolo, G; Santacaterina, I; Santini, V; Spiriti, MA; Stamatoullas, A; Voso, MT; Zini, G | 1 |
| Komrokji, RS | 1 |
| Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A | 1 |
| Godeau, B | 1 |
| Aivado, MA; Bruns, I; Erickson-Miller, CL; Kawahara, M; Luciano, JP; Parekh, S; Steidl, U; Verma, A; Will, B | 1 |
| Sekeres, MA | 1 |
| Leitch, HA; Vickars, LM | 1 |
| Carraway, HE; Gore, SD; Loaiza-Bonilla, A | 1 |
| Steensma, DP | 2 |
| Kalpadakis, C; Kozana, A; Mavroudi, I; Papadaki, HA; Pavlaki, K; Pontikoglou, C; Psyllaki, M; Pyrovolaki, K | 1 |
| Andreeff, M; Beran, M; Cahill, A; Clairmont, C; Cortes, J; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, F; Jeha, S; Kantarjian, H; Koller, C; Sznol, M; Thomas, D; Verstovsek, S | 1 |
13 review(s) available for hydrazine and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Lowering the boom on lower-risk myelodysplastic syndromes.
Topics: Activin Receptors, Type II; Aged; Antilymphocyte Serum; Benzoates; Bone Marrow Cells; Female; Hematinics; Humans; Hydrazines; Immunoglobulin Fc Fragments; Lenalidomide; Mutation; Myelodysplastic Syndromes; Pyrazoles; Recombinant Fusion Proteins; Risk Factors; Thrombocytopenia | 2019 |
Thrombopoietin mimetics for patients with myelodysplastic syndromes.
Topics: Adult; Azacitidine; Benzoates; Blood Transfusion; Decitabine; Female; Hemorrhage; Humans; Hydrazines; Lenalidomide; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Pyrazoles; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Thalidomide; Thrombocytopenia; Thrombopoietin | 2017 |
Eltrombopag in Immune Thrombocytopenia, Aplastic Anemia, and Myelodysplastic Syndrome: From Megakaryopoiesis to Immunomodulation.
Topics: Anemia, Aplastic; Benzoates; Humans; Hydrazines; Immunomodulation; Immunosuppression Therapy; Megakaryocytes; Myelodysplastic Syndromes; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin | 2019 |
Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders.
Topics: Antineoplastic Agents; Benzoates; Clinical Trials, Phase III as Topic; Drug Evaluation, Preclinical; Hematologic Diseases; Humans; Hydrazines; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Thrombopoietin; Thrombocytopenia | 2013 |
[Aplastic anemia].
Topics: Anemia, Aplastic; Antilymphocyte Serum; Benzoates; DNA Mutational Analysis; Drug Therapy, Combination; Early Medical Intervention; Hematopoietic Stem Cell Transplantation; Hemoglobinuria, Paroxysmal; Humans; Hydrazines; Immunosuppressive Agents; Myelodysplastic Syndromes; Prognosis; Pyrazoles; Randomized Controlled Trials as Topic; Shelterin Complex; Telomerase; Telomere-Binding Proteins; Transplantation Conditioning | 2014 |
Eltrombopag for treatment of thrombocytopenia-associated disorders.
Topics: Anemia, Aplastic; Animals; Benzoates; Chronic Disease; Clinical Trials as Topic; Hematopoietic Stem Cell Transplantation; Hepatitis, Chronic; Humans; Hydrazines; Myelodysplastic Syndromes; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Thrombopoiesis | 2015 |
Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies.
Topics: Antineoplastic Agents; Benzoates; Blood Platelets; Cell Differentiation; Gene Expression Regulation, Neoplastic; Hemorrhage; Humans; Hydrazines; Megakaryocytes; Myelodysplastic Syndromes; Platelet Transfusion; Prognosis; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Signal Transduction; Thrombocytopenia; Thrombopoietin | 2016 |
[Novel medical treatment modalities in hematology].
Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine | 2008 |
Treatment of MDS: something old, something new, something borrowed...
Topics: Azacitidine; Benzoates; Blood Transfusion; Bone Marrow Diseases; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Combined Modality Therapy; Decitabine; DNA-Cytosine Methylases; Glutathione; Hematinics; Humans; Hydrazines; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Risk; Thalidomide; Thrombopoietin | 2009 |
Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?
Topics: Aged; Anemia; Benzoates; Blood Component Transfusion; Chelation Therapy; Combined Modality Therapy; Deferoxamine; Hematopoietic Cell Growth Factors; Humans; Hydrazines; Iron; Iron Chelating Agents; Iron Overload; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Off-Label Use; Phlebotomy; Practice Guidelines as Topic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2009 |
Novel approaches for myelodysplastic syndromes: beyond hypomethylating agents.
Topics: Antineoplastic Agents; Benzoates; Enzyme Inhibitors; Humans; Hydrazines; Lenalidomide; Methyltransferases; Myelodysplastic Syndromes; Pyrazoles; Quality of Life; Thalidomide; Treatment Outcome | 2010 |
Novel therapies for myelodysplastic syndromes.
Topics: Adenine Nucleotides; Aged; Alkylating Agents; Antimetabolites; Arabinonucleosides; Clinical Trials as Topic; Clofarabine; DNA Repair; Drug Therapy, Combination; Drugs, Investigational; Enzyme Activation; Enzyme Inhibitors; Farnesyltranstransferase; Glutathione; Histone Deacetylase Inhibitors; Humans; Hydrazines; JNK Mitogen-Activated Protein Kinases; Myelodysplastic Syndromes; Quinolones; Sulfonamides; Therapies, Investigational | 2010 |
Hematopoietic growth factors in myelodysplastic syndromes.
Topics: Benzoates; Colony-Stimulating Factors; Darbepoetin alfa; Drug-Related Side Effects and Adverse Reactions; Epoetin Alfa; Erythropoietin; Filgrastim; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematinics; Humans; Hydrazines; Myelodysplastic Syndromes; Patient Selection; Polyethylene Glycols; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Recombinant Proteins; Thrombopoietin | 2011 |
12 trial(s) available for hydrazine and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome.
Topics: Active Transport, Cell Nucleus; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Hydrazines; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Triazoles | 2022 |
Phase Ib study of eltrombopag and azacitidine in patients with high-risk myelodysplastic syndromes and related disorders (the ELASTIC study).
Topics: Azacitidine; Benzoates; Drug Combinations; Humans; Hydrazines; Myelodysplastic Syndromes; Pyrazoles; Treatment Outcome | 2022 |
A sequential two-stage dose escalation study of eltrombopag in patients with myelodysplastic syndrome and thrombocytopenia after hypomethylating agent failure.
Topics: Azacitidine; Benzoates; Humans; Hydrazines; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrazoles; Thrombocytopenia; Treatment Outcome | 2020 |
Phase I trial of maintenance selinexor after allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndrome.
Topics: Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Transplantation Conditioning; Triazoles | 2020 |
Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Patient Safety; Prognosis; Survival Rate; Triazoles | 2020 |
Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
Topics: Aged; Benzoates; Female; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Placebos; Pyrazoles; Safety; Thrombocytopenia | 2018 |
A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Blood Platelets; Disease Progression; DNA Methylation; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Hydrazines; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Platelet Count; Prognosis; Pyrazoles; Treatment Outcome | 2019 |
A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Azacitidine; Benzoates; Blood Platelets; Cell Cycle; Drug Synergism; Drug Therapy, Combination; Female; Hematopoietic Stem Cells; Humans; Hydrazines; Ischemic Attack, Transient; Male; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Platelet Count; Pyrazoles; Receptors, Thrombopoietin; Remission Induction; Thrombocytopenia; Treatment Outcome; Venous Thrombosis | 2014 |
Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Double-Blind Method; Female; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Treatment Outcome | 2015 |
Eltrombopag Use in Patients With Chronic Myelomonocytic Leukemia (CMML): A Cautionary Tale.
Topics: Aged; Aged, 80 and over; Benzoates; Female; Humans; Hydrazines; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Pyrazoles; Treatment Outcome | 2016 |
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
Topics: Aged; Aged, 80 and over; Benzoates; Disease Progression; Female; Humans; Hydrazines; Male; Middle Aged; Myelodysplastic Syndromes; Platelet Count; Pyrazoles; Receptors, Thrombopoietin; Single-Blind Method; Thrombocytopenia; Treatment Outcome | 2017 |
A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Alkylating Agents; Area Under Curve; Humans; Hydrazines; Leukemia, Myeloid; Metabolic Clearance Rate; Middle Aged; Myelodysplastic Syndromes; Nausea; Sulfonamides; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vomiting | 2004 |
22 other study(ies) available for hydrazine and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Deferasirox combination with eltrombopag shows anti-myelodysplastic syndrome effects by enhancing iron deprivation-related apoptosis.
Topics: Apoptosis; Benzoates; Deferasirox; Humans; Hydrazines; Iron; Iron Chelating Agents; Myelodysplastic Syndromes; Pyrazoles; Thrombocytopenia | 2022 |
Selinexor synergizes with azacitidine to eliminate myelodysplastic syndrome cells through p53 nuclear accumulation.
Topics: Azacitidine; Humans; Hydrazines; Myelodysplastic Syndromes; Neoplasms; Triazoles; Tumor Suppressor Protein p53 | 2022 |
Long-Term Safety and Efficacy of Eltrombopag for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia: Results of the ASPIRE Extension Study.
Topics: Benzoates; Humans; Hydrazines; Leukemia, Myeloid, Acute; Leukopenia; Myelodysplastic Syndromes; Thrombocytopenia; Treatment Outcome | 2023 |
Eltrombopag in Lower-Risk Myelodysplastic Syndrome: Revival of Its Use in Thrombocytopenia.
Topics: Benzoates; Humans; Hydrazines; Myelodysplastic Syndromes; Thrombocytopenia | 2023 |
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzoates; Humans; Hydrazines; Middle Aged; Myelodysplastic Syndromes; Pyrazoles; Thrombopoiesis | 2021 |
Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria.
Topics: Age of Onset; Anemia, Aplastic; Antibodies, Monoclonal, Humanized; Benzoates; Bone Marrow; Chromosome Aberrations; Chromosomes, Human, Pair 7; Clonal Evolution; Clone Cells; Disease Progression; Granulocyte Colony-Stimulating Factor; Hemoglobinuria, Paroxysmal; Humans; Hydrazines; Leukemia, Myeloid, Acute; Models, Biological; Monosomy; Mutation; Myelodysplastic Syndromes; Oncogene Proteins, Fusion; Pyrazoles; Selection, Genetic; Telomere Shortening | 2020 |
Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndrome.
Topics: Benzoates; Hematopoiesis; Humans; Hydrazines; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrazoles | 2020 |
Eltrombopag for myelodysplastic syndromes or chronic myelomonocytic leukaemia with no excess blasts and thrombocytopenia: a French multicentre retrospective real-life study.
Topics: Aged; Aged, 80 and over; Benzoates; Blood Platelets; Female; France; Humans; Hydrazines; Leukemia, Myelomonocytic, Chronic; Male; Myelodysplastic Syndromes; Pyrazoles; Receptors, Thrombopoietin; Retrospective Studies; Thrombocytopenia | 2021 |
Preclinical evaluation of eltrombopag in a PDX model of myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Animals; Apoptosis; Benzoates; Cell Proliferation; Female; Humans; Hydrazines; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Myelodysplastic Syndromes; Prognosis; Pyrazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2022 |
Eltrombopag reduces clinically relevant thrombocytopenic events in higher risk MDS and AML.
Topics: Benzoates; Clinical Trials as Topic; Humans; Hydrazines; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrazoles; Risk; Thrombocytopenia | 2018 |
Eltrombopag use in higher risk myeloid cancers: fitting a square "pag" into a round hole?
Topics: Benzoates; Clinical Trials as Topic; Humans; Hydrazines; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrazoles; Risk | 2019 |
Eltrombopag induces major non-toxic hypersiderraemia.
Topics: Aged; Allografts; Anemia, Hypochromic; Benzoates; Female; Humans; Hydrazines; Myelodysplastic Syndromes; Pyrazoles; Stem Cell Transplantation | 2019 |
Use of eltrombopag in aplastic anemia in Europe.
Topics: Adult; Aged; Anemia, Aplastic; Benzoates; Drug Evaluation; Drug Utilization; Europe; Female; Follow-Up Studies; Humans; Hydrazines; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Proportional Hazards Models; Pyrazoles; Receptors, Thrombopoietin; Retrospective Studies; Young Adult | 2019 |
Use of eltrombopag for the treatment of thrombocytopenia in hypoplastic myelodysplastic syndrome.
Topics: Aged, 80 and over; Benzoates; Bone Marrow; Erythrocyte Transfusion; Female; Hemorrhagic Disorders; Humans; Hydrazines; Myelodysplastic Syndromes; Platelet Transfusion; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia | 2014 |
Effect of thrombopoietin-receptor agonists on a proliferation-inducing ligand (APRIL) plasma levels in patients with immune thrombocytopaenia.
Topics: Aged; Benzoates; Case-Control Studies; Female; Humans; Hydrazines; Immunoglobulins, Intravenous; Male; Middle Aged; Myelodysplastic Syndromes; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin; Tumor Necrosis Factor Ligand Superfamily Member 13 | 2014 |
Eltrombopag can overcome the anti-megakaryopoietic effects of lenalidomide without increasing proliferation of the malignant myelodysplastic syndrome/acute myelogenous leukemia clone.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Benzoates; Cell Line, Tumor; Cell Proliferation; Clonal Evolution; Female; Humans; Hydrazines; Lenalidomide; Leukemia, Myeloid, Acute; Male; Megakaryocyte Progenitor Cells; Middle Aged; Myelodysplastic Syndromes; Pyrazoles; Thalidomide; Thrombopoiesis | 2014 |
Disease characteristics and prognosis of myelodysplastic syndrome presenting with isolated thrombocytopenia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Benzoates; Decitabine; Female; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Risk; Thrombocytopenia; Thrombopoietin | 2017 |
Eltrombopag: liver toxicity, kidney injury or assay interference?
Topics: Benzoates; Bilirubin; Chemical and Drug Induced Liver Injury; Creatinine; Drug Monitoring; Female; Humans; Hydrazines; Kidney; Kidney Function Tests; Liver Function Tests; Myelodysplastic Syndromes; Pyrazoles | 2016 |
Use of eltrombopag for treatment of myelodysplastic syndromes.
Topics: Benzoates; Dose-Response Relationship, Drug; Humans; Hydrazines; Myelodysplastic Syndromes; Pyrazoles; Treatment Outcome | 2017 |
[Thrombopoietin-receptor agonists: a revolution in the therapeutic strategies of immune thrombocytopenic purpura?].
Topics: Administration, Oral; Adult; Antiviral Agents; Benzoates; Carrier Proteins; Controlled Clinical Trials as Topic; Drug Therapy, Combination; Female; Hepatitis C; Humans; Hydrazines; Immunoglobulins, Intravenous; Injections, Subcutaneous; Interferons; Myelodysplastic Syndromes; Placebos; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Ribavirin; Splenectomy; Thrombocytopenia; Thrombopoietin; Time Factors | 2009 |
Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome.
Topics: Animals; Apoptosis; Benzoates; Bone Marrow Cells; Cell Differentiation; Cell Proliferation; Dose-Response Relationship, Drug; Hematopoiesis; Humans; Hydrazines; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Male; Megakaryocytes; Mice; Mice, Inbred NOD; Myelodysplastic Syndromes; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Xenograft Model Antitumor Assays | 2009 |
Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome.
Topics: Aged; Aged, 80 and over; Antigens, CD34; Apoptosis; Benzoates; Blotting, Western; Bone Marrow Cells; Cell Proliferation; Female; Humans; Hydrazines; Male; Megakaryocyte Progenitor Cells; Middle Aged; Myelodysplastic Syndromes; Pyrazoles; Receptors, Thrombopoietin; Risk Factors; Thrombopoiesis; Tumor Cells, Cultured | 2011 |